Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Lupin acquires GAVIS...

    Lupin acquires GAVIS Pharma

    Written by savita thakur thakur Published On 2016-03-10T11:59:59+05:30  |  Updated On 10 March 2016 11:59 AM IST
    New Delhi: Drug major Lupin said it has completed the acquisition of privately held US-based GAVIS Pharmaceuticals LLC and Novel Laboratories (GAVIS).

    Lupin had announced the acquisition on July 23, 2015.

    The acquisition enhances the company's scale in the US generic market and also broadens its pipeline in dermatology, controlled substance products and other high-value and niche generics, Lupin said in a statement.

    Lupin CEO Vinita Gupta said: "The GAVIS portfolio augments our US business and niche generic pipeline. We plan to leverage the formulation expertise of Gavis to enhance both Lupin's generic as well as specialty pipeline."

    GAVIS brings to Lupin a highly skilled US-based manufacturing and research organisation which would complement its Florida-based R&D centre for inhalation products.

    GAVIS' New-Jersey based manufacturing facility will become Lupin's first manufacturing site in the US.

    GAVIS is a privately held company, specialising in formulation development, manufacturing, packaging, sales, marketing and distribution of pharmaceutical products.

    It has 62 abbreviated new drug application (ANDA) filings pending approval with the US FDA and a pipeline of over 65 plus products under development GAVIS' pending approvals address a market of over $9 billion.

    The combined company will have a portfolio of over 120 in-market products, more than 185 cumulative filings pending approval and a deep pipeline of products under development for the US.

    The acquisition creates the 5th largest pipeline of ANDA filings with US FDA, catering to a $63.8-billion market.

    Lupin shares were trading 0.33 per cent up at Rs 1,822.75 during the afternoon session on BSE.
    Abbreviated New Drug ApplicationAcquisitionANDAGAVISLupinUS Food & Drug AdministrationUSFDAVinita Gupta
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok